Therapy Areas: Respiratory
Kelun-Biotech publishes phase III data for trastuzumab botidotin in HER2-positive breast cancer
14 September 2026 - Chinese biopharmaceutical company Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) on Monday announced that it has published phase III results for its HER2-targeted an...
GSK reports positive Jideytro data supporting potential first-line lung cancer use
14 September 2026 - Biopharmaceutical company GSK plc (LSE: GSK) (NYSE: GSK) on Monday reported positive registrational Phase I/II ARROS-1 data for Jideytro (zidesamtinib) in previously untreated ROS1...
Akeso presents positive results from registrational Phase III study of ivonescimab
14 September 2026 - Chinese biopharmaceutical company Akeso Inc (HK:9926) announced on Sunday the presentation of positive overall survival (OS) results from the randomised, double-blind, multicentre,...
Insilico Medicine doses first patient in Phase III trial of rentosertib
10 September 2026 - Clinical-stage biotechnology company Insilico Medicine (HKEX:3696) announced on Wednesday that it has dosed the first patient with rentosertib (known as ISM001-055 / INS018_055) in...
Altesa BioSciences presents positive vapendavir clinical data at ERS International Congress 2026
9 September 2026 - Altesa BioSciences, a clinical-stage pharmaceutical company focused on chronic lung diseases including COPD and asthma, announced on Tuesday new clinical data showing that its inves...
Clover Biopharmaceuticals reports positive Phase 2 trial data for respiratory combination vaccine candidates
7 September 2026 - Chinese biotechnology company Clover Biopharmaceuticals Ltd (HKEX:02197) announced on Sunday positive preliminary data from a Phase 2 clinical trial in older adults in Australia eva...